2206 related articles for article (PubMed ID: 33456579)
21. Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotype.
Dong H; Yang Y; Gao C; Sun H; Wang H; Hong C; Wang J; Gong F; Gao X
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217759
[TBL] [Abstract][Full Text] [Related]
22. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
Chong L; Jiang YW; Wang D; Chang P; Xu K; Li J
J Nanobiotechnology; 2023 Oct; 21(1):401. PubMed ID: 37907987
[TBL] [Abstract][Full Text] [Related]
23. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
24. TGFβ-specific T cells induced by a TGFβ-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblasts.
Perez-Penco M; Lara de la Torre L; Lecoq I; Martinenaite E; Andersen MH
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417917
[TBL] [Abstract][Full Text] [Related]
25. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
26. Selective targeting of tumor associated macrophages in different tumor models.
Kakoschky B; Pleli T; Schmithals C; Zeuzem S; Brüne B; Vogl TJ; Korf HW; Weigert A; Piiper A
PLoS One; 2018; 13(2):e0193015. PubMed ID: 29447241
[TBL] [Abstract][Full Text] [Related]
27. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
28. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma.
Sun D; Luo T; Dong P; Zhang N; Chen J; Zhang S; Dong L; Janssen HLA; Zhang S
J Cell Biochem; 2020 Apr; 121(4):2828-2838. PubMed ID: 31692069
[TBL] [Abstract][Full Text] [Related]
29. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
[TBL] [Abstract][Full Text] [Related]
30. Targeting tumor-associated macrophages as an antitumor strategy.
Cheng N; Bai X; Shu Y; Ahmad O; Shen P
Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
[TBL] [Abstract][Full Text] [Related]
31. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
[TBL] [Abstract][Full Text] [Related]
32. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
33. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
34. M2 polarization of tumor-associated macrophages is dependent on integrin β3 via peroxisome proliferator-activated receptor-γ up-regulation in breast cancer.
Shu Y; Qin M; Song Y; Tang Q; Huang Y; Shen P; Lu Y
Immunology; 2020 Aug; 160(4):345-356. PubMed ID: 32311768
[TBL] [Abstract][Full Text] [Related]
35. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T; Aiba S
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
[TBL] [Abstract][Full Text] [Related]
36. Tramadol suppresses growth of orthotopic liver tumors via promoting M1 macrophage polarization in the tumor microenvironment.
Wang L; Guo W; Guan H; Yan N; Cai X; Zhu L
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4205-4218. PubMed ID: 38041778
[TBL] [Abstract][Full Text] [Related]
37. Antitumor properties of triptolide: phenotype regulation of macrophage differentiation.
Li H; Li L; Mei H; Pan G; Wang X; Huang X; Wang T; Jiang Z; Zhang L; Sun L
Cancer Biol Ther; 2020; 21(2):178-188. PubMed ID: 31663424
[TBL] [Abstract][Full Text] [Related]
38. Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective.
Xiao Y; Zhang L; Zhu J; Zhang Y; Yang R; Yan J; Huang R; Zheng C; Xiao W; Huang C; Wang Y
Biomed Pharmacother; 2021 Nov; 143():112105. PubMed ID: 34560533
[TBL] [Abstract][Full Text] [Related]
39. Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin.
Tan HY; Wang N; Man K; Tsao SW; Che CM; Feng Y
Cell Death Dis; 2015 Oct; 6(10):e1942. PubMed ID: 26492375
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulation of Tumor Microenvironment by Arginine-Loaded Iron Oxide Nanoparticles for Gaseous Immunotherapy.
Wu X; Cheng Y; Zheng R; Xu K; Yan J; Song P; Wang Y; Rauf A; Pan Y; Zhang H
ACS Appl Mater Interfaces; 2021 May; 13(17):19825-19835. PubMed ID: 33881837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]